Today: 24 June 2026
Aditxt (NASDAQ:ADTX) stock rally triggers questions around old share figures after latest SEC filing
24 June 2026
2 mins read

Aditxt (NASDAQ:ADTX) stock rally triggers questions around old share figures after latest SEC filing

NEW YORK, June 24, 2026, 07:14 (EDT)

  • Aditxt shares finished Tuesday at roughly 4.2 cents, jumping 117.19%. The stock was just below 4.1 cents early Wednesday before the regular Nasdaq open.
  • Aditxt reported 997,976,543 common shares outstanding as of June 22, but some free finance sites still listed about 816,000 shares.
  • Aditxt’s new share count slashes the size of reported stakes, dropping a previously disclosed 10.9% position to around 0.34% under the updated denominator.

Aditxt Inc’s runup is turning into a stress test for market data feeds. A new filing shows its share count is over 1,200 times what’s still posted on certain retail platforms.

Aditxt said in a filing Tuesday it had 997,976,543 common shares issued and outstanding as of June 22. Google Finance listed 816,000 shares and a market value near $32,670, with Robinhood showing a market cap of $33,370. But at Tuesday’s close of about $0.0417 a share and using Aditxt’s numbers, equity value comes to roughly $41.6 million.

That’s important for micro-cap traders who screen stocks by market cap, float or ownership. If the denominator is outdated, a stock can appear much smaller, more thinly traded, or easier to take over than it actually is based on current numbers.

Aditxt (NASDAQ:ADTX) finished Tuesday at $0.042, up 117.19%, Google Finance data show. Shares sat near $0.041 in premarket action ahead of the regular Nasdaq hours, 9:30 a.m. to 4 p.m. Eastern.

Takeover Time 2026 LLC flagged a possible share-count problem in its new Schedule 13D. The filing is required for investors who hit 5% ownership in a U.S. company and may want to influence it. Takeover Time said it bought 3,420,439 Aditxt shares on June 12 for around $50,000, giving it a 10.9% stake. But the filing also suggested the public share count from the issuer looked out of date.

Aditxt’s June 22 share count puts the 3,420,439 shares at about 0.34% of the company, not 10.9%. Takeover Time said it bought the stake for investment, with no current plans to influence or change control at Aditxt.

Two passive-holder filings had the same issue. Tai Wey Ann listed 100,000 shares, or 12.3%, in a Schedule 13G, the shorter form for passive investors. Emil Cristian Burciu showed 45,000 shares, or 5.5%. Based on Aditxt’s latest share count, those holdings are closer to 0.01% and 0.005%.

Aditxt said it bumped its senior secured convertible note deal to $6.25 million in principal and sold an extra $769,230.77 in notes for $500,000 cash. The notes sold under original issue discount, so cash in is lower than the debt amount on the books. The debt is backed by almost all of Ignite Proteomics’ assets and Aditxt’s stake in Ignite.

Ignite is what investors are trying to price. Aditxt announced earlier this month it signed a deal to value Ignite at around $150 million, planning to combine Ignite with a SPAC, which would take Ignite public on its own. Jeff Busch, who serves as both interim CEO of Aditxt and CEO of Ignite, said in that statement: “Aditxt owns 100% of Ignite.” Business Wire

Wild action hit health-care microcaps, with Aditxt up 151.6% in regular trade Tuesday, Benzinga said. Atlantic International added 143.31%. Boundless Bio jumped 85.35%. Aditxt’s move tied to ownership and financing instead of a clinical update or earnings numbers.

The trade could go against buyers if they were expecting old ownership stakes. The notes put Ignite assets behind new debt. The SPAC needs shareholder okays, funding and listing sign-offs. Aditxt says its own Nasdaq listing still depends on staying within Nasdaq rules.

Michał Rogucki is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic developments. A graduate of Humboldt University of Berlin, he previously worked in investment research and market analysis before transitioning to financial journalism. He covers the trends and events that matter most to investors worldwide.

Stock Market Today

  • Micron, Qualcomm, Intel Lead AI Stocks Recovery Amid Market Rebound
    June 24, 2026, 9:12 AM EDT. Micron Technology, Qualcomm, and Intel spearheaded a recovery rally in AI-focused stocks following a sharp decline in the previous session. The bounce back highlights renewed investor confidence in semiconductor and technology sectors linked to artificial intelligence. This reversal comes as broader market sentiment improves, with foundational tech shares regaining ground after recent losses. Industry observers note the recovery underscores the volatility but ongoing interest in AI-driven innovation stocks. The rebound may signal a stabilization phase ahead in technology equities, with key players like Micron and Qualcomm regaining upward momentum.
Arqit Quantum (NASDAQ:ARQQ) climbs after fresh U.S. quantum security deals, SEC filing

Arqit Quantum (NASDAQ:ARQQ) climbs after fresh U.S. quantum security deals, SEC filing

24 June 2026
Arqit Quantum surged 35.6% after U.S. executive orders on June 22 spotlighted post-quantum cryptography, the encryption Arqit sells, with shares quoted up again premarket; a Millennium-linked group briefly held over 5% but fell below that threshold, and a $7 million legal settlement was approved, resolving all U.S. class actions against the company.
Tencent stock up as firm tests WeCom AI tool, files share buyback

Tencent stock up as firm tests WeCom AI tool, files share buyback

24 June 2026
Tencent soared 3.38% to HK$428.80 after its WeCom app began limited rollout of Dayuan, an AI agent built on DeepSeek V4, with the news helping push shares up over 5% in afternoon trade; Tencent also repurchased 1.183 million shares for HK$500.7 million, while the AI push raises spending and adoption risks remain.
Ambu falls after Danske Bank downgrades on urology concerns

Ambu falls after Danske Bank downgrades on urology concerns

24 June 2026
Ambu shares plunged 9.4% to 56.75 DKK after Danske Bank downgraded the stock to “sell” and slashed its price target to 58 DKK, citing faster-than-expected competition and price pressure in urology, weak ureteroscope traction, and a limited product portfolio versus rivals, despite ongoing share buybacks and recent endoscopy growth.
Backblaze rally leaves CoreWeave deal below stated price
Previous Story

Backblaze rally leaves CoreWeave deal below stated price

Samsung rally puts buyback plan under investor lens
Next Story

Samsung rally puts buyback plan under investor lens

Go toTop